MARCHF2 and breast carcinoma: Moreover, using the Prognoscan analysis platform [27], we found that the expression levels of MARCH1, MARCH2, MARCH5, MARCH8, and MARCH10 were positively correlated with the overall survival of breast cancer patients, whereas higher expression levels of MARCH3, MARCH6, MARCH7, and MARCH9 had the opposite correlation with worse overall survival, as shown in Kaplan–Meier plots (Figure 2).